bronchial pneumonia contagious - Fluoroquinolone Antibiotics Classification, Uses and Side Effects
Bronchitis Remedy Natural Bronchitis Treatment Treat Bronchitis Naturally Bronchitis cure
 

Fluoroquinolone Antibiotics Classification, Uses and Side Effects

The fluoroquinolones are a relatively new group of antibiotics. Fluoroquinolones were first introduced in 1986, but they are really modified quinolones, a class of antibiotics, whose accidental discovery occurred in the early 1960.

Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin is the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin are the most widely used second-generation quinolones because of their availability in oral and intravenous formulations and their broad set of FDA-labeled indications.


Bronovil Natural Bronchitis Remedy

irritable bowel syndrome (Bronchitis) natural remedy Heals bronchitis quickly and naturally.

Scientifically Formulated Based on Clinical Research to:
  • Stop persistent cough
  • Prevent virus from attacking your lungs
  • Boost your immune system
  • Naturally relieve pain and fever
  • Relieve lung inflamation
  • Breathe easier
  • Feel stronger in no time

User Ratings 4.9 / 5
Bronchitis Remedy


  Fluoroquinolones advantages: Ease of administration Daily or twice daily dosing Excellent oral absorption Excellent tissue penetration Prolonged half-lives Significant entry into phagocytic cells Efficacy Overall safety The completion of this article on Chronic Bronchitis was our prerogative since the past one month. However, we completed it within a matter of fifteen days!

Gastrointestinal effects. The most common adverse events experienced with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in 1 to 5% of patients. CNS effects. Headache, dizziness, and drowsiness have been reported with all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, have been reported in patients receiving trovafloxacin. Seizures may develop within 3 to 4 days of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones should be avoided in patients with a history of convulsion, cerebral trauma, or anoxia. No seizures have been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. With the older non-fluorinated quinolones neurotoxic symptoms such as dizziness occurred in about 50% of the patients. Phototoxicity. Exposure to ultraviolet A rays from direct or indirect sunlight should be avoided during treatment and several days (5 days with sparfloxacin) after the use of the drug. The degree of phototoxic potential of fluoroquinolones is as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin. Musculoskeletal effects. Concern about the development of musculoskeletal effects, evident in animal studies, has led to the contraindication of fluoroquinolones for routine use in children and in women who are pregnant or lactating. Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within one week of discontinuation of therapy, spontaneous ruptures have been reported as long as nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant use of corticosteroids. Hepatoxicity. Trovafloxacin use has been associated with rare liver damage, which prompted the withdrawal of the oral preparations from the U.S. market. However, the IV preparation is still available for treatment of infections so serious that the benefits outweigh the risks. Cardiovascular effects. The newer quinolones have been found to produce additional toxicities to the heart that were not found with the older compounds. Evidence suggests that sparfloxacin and grepafloxacin may have the most cardiotoxic potential. Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the effects have been mild. Hypersensitivity. Hypersensitivity reactions occur only occasionally during quinolone therapy and are generally mild to moderate in severity, and usually resolve after treatment is stopped. This can be considered to be a valuable article on Chronic Bronchitis. It is because there is so much to learn about Chronic Bronchitis here.

Classification of Fluoroquinolones As a group, the fluoroquinolones have excellent in vitro activity against a wide range of both gram-positive and gram-negative bacteria. The newest fluoroquinolones have enhanced activity against gram-positive bacteria with only a minimal decrease in activity against gram-negative bacteria. Their expanded gram-positive activity is especially important because it includes significant activity against Streptococcus pneumoniae. Using great confidence in ourselves, we endeavored to write such a long article on Chronic Bronchitis. Such is the amount of matter found on Chronic Bronchitis.

Fluoroquinolones are approved for use only in people older than 18. They can affect the growth of bones, teeth, and cartilage in a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating that these drugs have the potential to cause teratogenic or embryocidal effects. Giving fluoroquinolones during pregnancy is not recommended unless the benefits justify the potential risks to the fetus. These agents are also excreted in breast milk and should be avoided during breast-feeding if at all possible.

Fluoroquinolones disadvantages: Tendonitis or tendon rupture Multiple drug interactions Not used in children Newer quinolones produce additional toxicities to the heart that were not found with the older agents

Urinary tract infections (norfloxacin, lomefloxacin, enoxacin, ofloxacin, ciprofloxacin, levofloxacin, gatifloxacin, trovafloxacin) Lower respiratory tract infections (lomefloxacin, ofloxacin, ciprofloxacin, trovafloxacin) Skin and skin-structure infections (ofloxacin, ciprofloxacin, levofloxacin, trovafloxacin) Urethral and cervical gonococcal infections (norfloxacin, enoxacin, ofloxacin, ciprofloxacin, gatifloxacin, trovafloxacin) Prostatitis (norfloxacin, ofloxacin, trovafloxacin) Acute sinusitis (ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin (Avelox), trovafloxacin) Acute exacerbations of chronic bronchitis (levofloxacin, sparfloxacin (Zagam), gatifloxacin, moxifloxacin, trovafloxacin) Community-acquired pneumonia (levofloxacin, sparfloxacin, gatifloxacin, moxifloxacin, trovafloxacin) The sources used for the information for this article on Chronic Bronchitis are all dependable ones. This is so that there be no confusion in the authenticity of the article.

 
Save 40% Off The Retail Price

What People Said About Bronovil Bronchitis Treatment
"When I had bronchitis, I couldn't stop coughing and was unable to sleep, Bronovil helped me to get my life back. thank you!" Michael A., OH
Bronchitis treatment


Third Generation. The third-generation fluoroquinolones are separated into a third class because of their expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens such as Mycoplasma pneumoniae and Chlamydia pneumoniae. Although the third-generation agents retain broad gram-negative coverage, they are less active than ciprofloxacin against Pseudomonas species. It was with great relief we ended writing on Bronchitis. There was just too much information to write, that we were starting to lose hopes on it's completion!

Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while maintaining the gram-positive and gram-negative activity of the third-generation drugs. They also retain activity against Pseudomonas species comparable to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).

First Generation. The first-generation agents include cinoxacin and nalidixic acid, which are the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were used primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing than the newer quinolones, and they are more susceptible to the development of bacterial resistance. We have also translated parts of this composition into French and Spanish to facilitate easier understanding of Bronchitis. In this way, more people will get to understand the composition.

Conditions treated with Fluoroquinolones: indications and uses The newer fluoroquinolones have a wider clinical use and a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones have an important role in the treatment of community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of the fluoroquinolones range from 3 -20 hours, allowing for once or twice daily dosing. Dwelving into the interiors of Bronchitis has led us to all this information here on Bronchitis. Bronchitis do indeed have a lot to tell!Dwelving into the interiors of Bronchitis has led us to all this information here on Bronchitis. Bronchitis do indeed have a lot to tell!

Because of their expanded antimicrobial spectrum, third-generation fluoroquinolones are useful in the treatment of community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, which are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin. The information available on Chronic Bronchitis is infinite. There just seems to be so much to learn about, and to write about on Chronic Bronchitis.

The newer fluoroquinolones have a wider clinical use and a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones have an important role in the treatment of community-acquired pneumonia and intra-abdominal infections.

Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, as well as some gram-positive and atypical pathogen coverage. Compared with first-generation quinolones, these drugs have broader clinical applications in the treatment of complicated urinary tract infections and pyelonephritis, sexually transmitted diseases, selected pneumonias and skin infections.

The fluoroquinolones are a family of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of the group is nalidixic acid, discovered in 1962 by Lescher and colleagues. The first fluoroquinolones were widely used because they were the only orally administered agents available for the treatment of serious infections caused by gram-negative organisms, including Pseudomonas species. It was with keen interest that we got about to writing on Bronchitis. Hope you read and appreciate it with equal interest.

Because of concern about hepatotoxicity, trovafloxacin therapy should be reserved for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), and the drug should be taken for no longer than 14 days. Aiming high is our motto when writing about any topic. In this way, we tend to add whatever matter there is about Chronic Bronchitis, rather than drop any topic.

Side effects The fluoroquinolones as a class are generally well tolerated. Most adverse effects are mild in severity, self-limited, and rarely result in treatment discontinuation. However, they can have serious adverse effects. We are satisfied with this end product on Chronic Bronchitis. It was really worth the hard work and effort in writing so much on Chronic Bronchitis.




Yury Bayarski is the author of OriginalDrugs.com - website, offering patches and natural health products. More information about antibiotic medications is available on author's website.


 
 
     
 
 





Learn More about Natural Bronchitis Remedy

Introduction: Before trying to get rid of mucous it is pertinent to know what it is and what causes it. Mucous is a contagion, which is caused by bacteria. In short, the bacteria that causes cold generally causes mucous. Where are mucous generally found? Mucous are found in the sinus area, which is near the eyes and nose, bronchitis and throat. You need to do away with the mucous in the...


Chronic bronchitis is defined as a long term inflammation or swelling of the bronchi.' This can result in heightened production of mucus and may be accompanied by other side effects.' To be classified as chronic bronchitis, a harsh cough and expectoration (coughing up of mucus) must occur on most days, for no less than three months of the year, for two or more years in a row.' This does not...


Acute bronchitis is a common respiratory disease that causes inflammation of the bronchial mucosal membranes. Unlike chronic forms of the disease, acute bronchitis has a rapid onset and generates more intense symptoms. However, acute bronchitis doesn't have a recurrent character and thus its generated symptoms don't persist in time. Due to the fact that the clinical manifestations of acute...


When medical professionals enter their career, they have to be careful when diagnosing a patient. Often times, symptoms of one illness can be having symptoms to another illness. It's because of this that doctors have to be very careful and provide an accurate diagnosis, combine that with the right type of treatment of medicine. Bronchitis is a condition in which the bronchial tubes are...


bronchial pneumonia asthma | bronchial pneumonia treatment | bronchial pneumonia lungs | bronchial pneumonia bacteria | bronchial pneumonia contagious |







 
 
 
 
 
 
 
(c) 2014 bronchitis911.info
Contact Us | About Us | Privacy Policy | RSS Feed | bronchial pneumonia contagious